Abbvie Inc (ABBV) Stock Price, Quote & News

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 847 932 7900

Website: www.abbvie.com

Address:

1 North Waukegan Road, North Chicago, United States

MarketBeat May. 26 at 4:01 PM

https://marketbeat.com/a/8675686/ $ABBV 5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade

0 · Reply

Loudermilk64 May. 26 at 3:53 PM

$ABBV depreasing…

0 · Reply

crtlabz May. 26 at 2:24 PM

$ABBV geez!

0 · Reply

PlutoAnalyses May. 26 at 9:42 AM

Looking at the current state of the Anti-Obesity Market, it seems that a $VKTX acquisition would likely take one of a few forms. Either a company like $ABBV or $PFE, if they fail a trial or realize their asset isn’t sufficient, might decide to acquire their way into the market. Alternatively, a company with no existing Anti-Obesity exposure, such as $SAN, could choose to enter through an acquisition. It's both promising and somewhat concerning that nearly all the major players in the market have some form of Anti-Obesity asset. On one hand, this shows strong interest, but on the other, it suggests these assets might need to fail first before we see any significant moves.

2 · Reply

jenfierf May. 26 at 9:01 AM

$ABBV appears to be doing well. Bulls are still in control over $215 thanks to a defensive setup and strong volume. observing a move in the direction of $220.

0 · Reply

Mike22332233 May. 25 at 11:38 PM

$SLS Are you ready for Tuesday Morning? ... UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! .. From here, SLS could return 1,650%-2,650% ... the single best asymmetrical investment I've seen in my 40+ years of investing !!! ... ALSO, this week I expect the twice delayed TO for $LSTA at $5.00 plus a CVR for another future possible $1.00, to move forward, and from current $3.14 price, to give me a +59% return ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I post my Special Situation Stocks that have potential for FAST & HUGE profits ... which I always plow back into more $SLS !!!

1 · Reply

StockTwitsGhost May. 25 at 10:17 PM

$IRWD $ABBV Approved: NDA 202811/S-023 for LINZESS/LINACLOTIDE functional constipation in children ages 2 to 5, AbbVie, SUPPL-23, action date 05/21/2026, Efficacy-New Patient Population. It’s right there on the primary Drugs@ FDA: FDA-Approved Drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch.process

0 · Reply

55X_ROI_Q1_2026 May. 25 at 7:55 PM

$SLS $ABBV Best Available Treatment / BAT for Control Arm Patients in the REGAL Trial, recently Failed 3 Large Phase 3 Trials. - including Failing the VIALE-M - Phase 3 Maintenance Trial for AML patients in First Remission (CR1). $ABBV Terminated the Trial at 116 Patients, and didn't make it out of the Safety Phase - they tried 7 different Dosing Schedules, all Oral IV Subq --- Aza+VEN Failed as a Maintenance treatment in CR1 - it is failed is the AML CR2 REGAL Control Arm. https://clinicaltrials.gov/study/NCT04102020?term=viale-M&viewType=Card&rank=1&tab=results Aza+VEN als FAILED the VIALE-T - Post Transplant Maintenance Phase 3. IT IS NOT COMPLICATED... $CING

0 · Reply

55X_ROI_Q1_2026 May. 25 at 5:12 PM

$SLS $ABBV It is Not Complicated.

0 · Reply

uhnyu678 May. 25 at 10:14 AM

$ABBV appears to be doing well. When dips continue to be purchased, it typically indicates that buyers are still in charge.

0 · Reply

AbbVie reports positive CHMP opinion for Maviret

May 22, 2026, 8:00 AM EDT - 4 days ago

AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection

May 21, 2026, 6:46 PM EDT - 4 days ago

AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

2026-05-21T20:19:37.000Z - 4 days ago

AbbVie’s Allergan Aesthetics receives positive CHMP opinion for Boey

May 21, 2026, 4:10 PM EDT - 4 days ago

Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults

2026-05-15T12:51:42.000Z - 11 days ago

AbbVie price target lowered to $235 from $236 at Evercore ISI

2026-05-14T20:15:24.000Z - 11 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks with 100%+ Payout Ratios, 5/14/26

ABT NEE

2026-05-14T11:07:12.000Z - 12 days ago

AbbVie price target raised to $298 from $294 at Piper Sandler

May 13, 2026, 2:20 PM EDT - 12 days ago

AbbVie Transcript: Bank of America Global Healthcare Conference 2026

May 9, 2026, 10:08 AM EDT - 17 days ago

AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting

May 8, 2026, 10:00 AM EDT - 18 days ago

AbbVie Transcript: AGM 2026

May 6, 2026, 8:00 AM EDT - 20 days ago

AbbVie to Present at the Bank of America Securities Healthcare Conference

2026-05-05T12:32:52.000Z - 21 days ago

AbbVie presented new data across its gastroenterology portfolio at the 2026 DDW

May 5, 2026, 8:05 AM EDT - 21 days ago

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

IBD

2026-05-04T12:13:35.000Z - 22 days ago

AbbVie price target raised to $236 from $232 at Evercore ISI

May 2, 2026, 8:45 AM EDT - 24 days ago

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

AZN GSK

May 1, 2026, 3:05 PM EDT - 24 days ago

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

May 1, 2026, 10:03 AM EDT - 25 days ago

Big Pharma M&A set for mega year as patent expiries drive deal urgency

BMY GILD GSK LLY

Apr 30, 2026, 3:00 PM EDT - 25 days ago

AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec

2026-04-30T18:00:46.000Z - 26 days ago

AbbVie price target raised to $278 from $270 at Morgan Stanley

2026-04-30T13:31:03.000Z - 26 days ago

AbbVie price target raised to $265 from $262 at Canaccord

Apr 30, 2026, 9:00 AM EDT - 26 days ago

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

2026-04-30T10:15:57.000Z - 26 days ago

AbbVie upgraded to Buy at BofA on durable growth

2026-04-30T10:14:18.000Z - 26 days ago

AbbVie upgraded to Buy from Neutral at BofA

Apr 29, 2026, 2:50 PM EDT - 26 days ago

AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?

2026-04-29T16:41:09.000Z - 27 days ago

AbbVie raises FY26 revenue view to about $67.3B from about $67B

2026-04-29T16:39:58.000Z - 27 days ago

AbbVie sees Q2 adjusted EPS $3.74-$3.78, consensus $3.74

2026-04-29T16:39:07.000Z - 27 days ago

AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’

Apr 29, 2026, 9:00 AM EDT - 27 days ago

AbbVie Earnings Call Transcript: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 27 days ago

AbbVie Earnings release: Q1 2026

Apr 29, 2026, 9:00 AM EDT - 27 days ago

AbbVie Quarterly report: Q1 2026

Apr 29, 2026, 8:32 AM EDT - 27 days ago

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

Apr 29, 2026, 7:50 AM EDT - 27 days ago

AbbVie tops quarterly expectations as newer immunology drugs offset Humira decline

Apr 29, 2026, 7:47 AM EDT - 27 days ago

AbbVie Reports First-Quarter 2026 Financial Results

Apr 28, 2026, 8:00 AM EDT - 4 weeks ago

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Apr 28, 2026, 7:00 AM EDT - 4 weeks ago

EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie

Apr 27, 2026, 8:05 AM EDT - 4 weeks ago

AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Apr 23, 2026, 4:19 PM EDT - 4 weeks ago

US FDA declines to approve AbbVie's wrinkle treatment

Apr 23, 2026, 4:05 PM EDT - 4 weeks ago

AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Apr 22, 2026, 12:59 PM EDT - 4 weeks ago

AbbVie to build $1.4 billion manufacturing campus in North Carolina

Apr 22, 2026, 12:02 PM EDT - 4 weeks ago

AbbVie Selects North Carolina for New $1.4 Billion Manufacturing Campus

Apr 20, 2026, 2:30 AM EDT - 5 weeks ago

Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases

Apr 14, 2026, 8:50 AM EDT - 6 weeks ago

Erin Lichy Gets Real About Her Natrelle® Breast Augmentation

Apr 13, 2026, 2:24 AM EDT - 6 weeks ago

Haisco Enters into Exclusive License Agreement with AbbVie to Develop Novel Medicines for Pain

Apr 12, 2026, 7:15 AM EDT - 6 weeks ago

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Apr 9, 2026, 2:00 PM EDT - 6 weeks ago

3 Dividend Aristocrats Whose Yields Can Help Combat Inflation

AMCR CVX

Apr 8, 2026, 1:38 PM EDT - 6 weeks ago

AbbVie files lawsuit to address 'outdated' drug discount eligibility program

Apr 8, 2026, 8:00 AM EDT - 6 weeks ago

BOTOX® Cosmetic (onabotulinumtoxinA) Empowers Women Entrepreneurs Through "The Confidence Collective" for Fourth Year

Apr 7, 2026, 9:53 AM EDT - 7 weeks ago

The price Americans pay for medicine has gotten horribly out of control. Here's how to fix it.

Apr 7, 2026, 9:00 AM EDT - 7 weeks ago

Allergan Aesthetics Third State-of-the-Art AMI Center Opens in Austin

Apr 3, 2026, 11:08 AM EDT - 7 weeks ago

Swiss industry body says US tariffs on pharmaceuticals will harm patients

AMGN AZN BMY MRK NVO

Apr 2, 2026, 5:34 PM EDT - 7 weeks ago

Trump Administration Unveils Up to 100% Tariff on Branded Drugs

AZN NVO AMGN BMY MRK

Apr 2, 2026, 5:33 PM EDT - 7 weeks ago

Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices

AMGN AZN BMY MRK NVO

Apr 2, 2026, 3:29 PM EDT - 7 weeks ago

Drugmakers face 100% tariff unless they cut prices or produce drugs in US

AZN NVO AMGN BMY MRK

Apr 2, 2026, 2:59 PM EDT - 7 weeks ago

Global pharma companies that have publicly announced Trump drug pricing agreements

AMGN AZN BMY MRK

Mar 31, 2026, 8:05 AM EDT - 2 months ago

Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting®

Mar 31, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Host First-Quarter 2026 Earnings Conference Call

Mar 27, 2026, 10:00 AM EDT - 2 months ago

AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting

Mar 24, 2026, 8:00 AM EDT - 2 months ago

AbbVie Named Official Pharmaceutical Partner of Major League Baseball

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing

Mar 23, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy filing

Mar 20, 2026, 12:11 PM EDT - 2 months ago

US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings

AMRX NVS OGN

Mar 19, 2026, 9:26 AM EDT - 2 months ago

Buy Or Fear AbbVie Stock At $210?

Mar 19, 2026, 3:00 AM EDT - 2 months ago

Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments with Comprehensive Global Survey and New Educational Solutions

Mar 18, 2026, 2:23 PM EDT - 2 months ago

TrumpRx lists many medicines at prices higher than paid in UK

AMGN AZN BMY GILD GSK JNJ LLY

Mar 17, 2026, 2:32 PM EDT - 2 months ago

Big drugmakers must face US overcharge claims on medications for low-income patients

AZN NVS SNY

Mar 13, 2026, 9:00 AM EDT - 2 months ago

New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row

Mar 10, 2026, 11:20 AM EDT - 2 months ago

AbbVie Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults

Mar 9, 2026, 8:00 AM EDT - 2 months ago

AbbVie Proxy statement: Proxy Filing

Mar 6, 2026, 8:26 AM EST - 2 months ago

These 3 Cash Flow Machines Provide Stability in Uncertain Markets

GILD V

Mar 3, 2026, 11:10 AM EST - 3 months ago

AbbVie Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 8:00 AM EST - 3 months ago

AbbVie to Present at the Leerink Partners Global Healthcare Conference

Mar 2, 2026, 8:30 AM EST - 3 months ago

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease

MarketBeat May. 26 at 4:01 PM

https://marketbeat.com/a/8675686/ $ABBV 5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade

0 · Reply

Loudermilk64 May. 26 at 3:53 PM

$ABBV depreasing…

0 · Reply

crtlabz May. 26 at 2:24 PM

$ABBV geez!

0 · Reply

PlutoAnalyses May. 26 at 9:42 AM

2 · Reply

jenfierf May. 26 at 9:01 AM

$ABBV appears to be doing well. Bulls are still in control over $215 thanks to a defensive setup and strong volume. observing a move in the direction of $220.

0 · Reply

Mike22332233 May. 25 at 11:38 PM

1 · Reply

StockTwitsGhost May. 25 at 10:17 PM

0 · Reply

55X_ROI_Q1_2026 May. 25 at 7:55 PM

0 · Reply

55X_ROI_Q1_2026 May. 25 at 5:12 PM

$SLS $ABBV It is Not Complicated.

0 · Reply

uhnyu678 May. 25 at 10:14 AM

$ABBV appears to be doing well. When dips continue to be purchased, it typically indicates that buyers are still in charge.

0 · Reply

55X_ROI_Q1_2026 May. 25 at 6:03 AM

$SLS $ABBV Since the IDMC Unblinded KEY Median Overall Survival and Immune Response data from the Ongoing Phase 3 Interim Analysis - SLS Market Value is up over 1,000%. Actual P3 MOS AND IR DATA. https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml

0 · Reply

Mike22332233 May. 25 at 12:11 AM

$SLS $MRK $PFE $ABBV UPDATED HR VALUE ... THE GPS READOUT will be GAME-CHANGING FOR CANCER SURVIVAL!!! ... Using all the data that the REGAL Trial has put out on enrollment trenches and cohort data, the 66 death&toxicity report, the 60 event report, and the 72 event report, And, then using Monte Carlo simulations based on Cox proportional hazards to be used in the FDA final statistical analysis … My conclusions is: EFFECTIVELY, those getting GPS that had an immune response (80% of them), are NOT PASSING AWAY!!! ... When trial ends at the 80th event, we will find that NONE of the 63 BAT arm are still living … While 46 of the 63 GPS arm will still be alive !!!! … As I've said before: The HR Value will be 0.27 to 0.33 which is UNHEARD OF AND GROUNDBREAKING!!! … It’s A NEW STANDARD OF Care !!!! …. It’s A $40 Bil VALUATION !!! … It’s A BIG PHARMA BIDDING WAR FINAL BO VALUE OF $222 !!! ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 to get all updates

3 · Reply

55X_ROI_Q1_2026 May. 24 at 11:55 PM

$SLS $ABBV IDMC Unblinded KEY Median Overall Survival and Immune Response data from the Ongoing Phase 3 Interim Analysis - Since then SLS Market Value is up over 1,000%. why do you think that is? https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml

0 · Reply

55X_ROI_Q1_2026 May. 24 at 10:18 PM

$SLS $ABBV do some due diligence on SLS before and after the IDMC Unblinded Select MOS and IR Data from the Phase 3 Interim Analysis - it told smart money GPS is Golden. https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml

0 · Reply

55X_ROI_Q1_2026 May. 24 at 9:13 PM

$SLS $CING $RILY while we are seeing extended, mirculous all pooled survival in the SLS REGAL Phase 3 Trial - the BAT Best Available Treatment for Control ARM Patients recently Failed 3 Large Phase 3 Trials conducted by $ABBV. - it is not complicated. - IDMC Unblinded Actual MOS and IR data from the Interim Analysis: IR in 80% of Tested Gps Patients. IR is Directly Correlated with Survival in all prior Gps Trials - including 2 Phase 2's for AML Remission. 64% IR Rate in the AML CR2 GPS Phase 2, achieved a Stat Sig 21 Month MOS 64% IR = 21 Month MOS / 80% IR in the P3 = > 21 month MOS

2 · Reply

Mike22332233 May. 24 at 8:03 PM

$SLS UPDATED ... Timeline/Price Prediction: ... SLS will jump to $18-$22 at 80th event ... and then RUN UP TO $55-$60 on GROUNDBREAKING readout results a month later !!! ... from there, it will drift up to the $75-$80 area over the next month ... and soon after, the opening BO Offer will be place at about $140-$160 ... After, a 3 way Bidding War --between $MRK, $PFE, and $ABBV -- the FINAL BO PRICE will be reached at $222 in Q4 of 2026 !!! ... If you agree, LIKE & FOLLOW me 👉 @Mike22332233 as I uncover and post my Special Situation Stocks that have potential for HUGE & QUICK profits ahead ... which I always plow back into more $SLS !!!

1 · Reply

Mike22332233 May. 24 at 7:39 PM

$SLS If you agree with what I will say, then LIKE this and FOLLOW me 👉 @Mike22332233 ... YES, I am VERY VERY BULLISH — I am playing this FOR A BUYOUT ONLY !! Based on research and what I know, this is my play: There is a 98+% chance the readout is positive and THEN I EXPECT 100% chance of a buyout at a MINIUM PRICE OF $50 to $75 (a $10 to $15 Billion valuation) and a MAXIMUM PRICE OF $150 to $175 (a $30 to $35 Billion valuation) within 3 months of the GPS Readout by one of the top 10 Big Pharma companies, most likely $MRK, $PFE or $ABBV ... There is a high chance that 2 or even 3 of these Big Pharma will get into a bidding war over buying $SLS, in which case my final Bidding War Buy Out price is $222 !!! … If you agree with what I will say, then LIKE this and FOLLOW me 👉 @Mike22332233 ...

2 · Reply

clan May. 24 at 3:38 PM

$MNKD 🧱🏁🏎 Inhalable mealtime insulin. #Afrezza #inhalemyinsulin FAST IN! FAST OUT! $AMGN $ABBV $SNY

1 · Reply

55X_ROI_Q1_2026 May. 24 at 6:19 AM

$SLS $ABBV While We are Seeing Miraculous ALL POOLED Survival, BAT for Control Arm Pstients FAILED 3 AML Trials and GPS was Proven Effective at Preventing Relapse and Extending Survival in all 7 Prior trials, Including 2 Phase 2 Trials for AML Remission Maintenance. it is not complicated. "What is the Longest Survival you see in CR2 in your Practice?".

0 · Reply

55X_ROI_Q1_2026 May. 24 at 12:14 AM

$SLS $ABBV it is Not Complicated... BAT - for Control Arm Patients FAILED A PHASE 3 TRIAL For AML Patients in FIRST REMISSION. Aza+VEN Recently FAILED 3 Large Phase 3 Trials for AML Maintenance. VIALE-M Phase 3 for CR 1 Remission Maintenance FAILED VIALE-T Phase 3 for Post Transplant Maintenance FAILED VERONA MDS/HIGH RISK AML Maintenance FAILED BAT - also FAILED in the SLS PHASE 3 TRIAL for Second Remission Maintenance.

0 · Reply

55X_ROI_Q1_2026 May. 23 at 7:27 PM

$SLS for all those interested in money. While we continue to see Miraculous ALL POOLED Survival Data, and wait for the 80th Event PR and ensuing Share Price Launch, Azacitidine +VEN the BAT - Best Available Treatment for the SLS Phase 3 CONTROL ARM Patients, Recently FAILED 3 Large Phase 3 Trials conducted by $ABBV. -- BAT FAILED the VIALE-M Trial for AML Patients in First Remission CR1 -- $ABBV Knows it Failed the SLS Phase 3 Second Remission CR2 Maintenance trial. The IDMC UNBLINDED ACTUAL MOS and IR DATA from the SLS Phase 3 INTERIM Analysis - Jan. Since then SLS Share PRICE/ Market Value/ Cash/ Institutional Investment is all + 10x .... SMART MONEY, SMARTER MONEY than the Retail Tools on ST Know - GPS is GOLDEN.

1 · Reply

Blockwave1 May. 23 at 2:28 PM

MASSIVE growth on Telegram 4,300+ members strong 🚀 The profits keep rolling in… no slowing down 🔥 Join the telegram channel:https://t.me/BlockWave10 ✅ $IBM 22 MAY 26 $240 CALL — 1,171% ✅ $HD 22 MAY 26 $415 CALL — 400% ✅ $IBM 29 MAY 26 $245 CALL — 400% ✅ $AAPL 22 MAY 26 $300 CALL — 263% ✅ $COST 22 MAY 26 $1,120 CALL — 203% ✅ $COST 22 MAY 26 $1,110 CALL — 201% ✅ $ABBV 22 MAY 26 $222.5 CALL — 156% THIS WEEK I dropped over 2,799%+ in FREE gains on STOCKTWITS 🔥

0 · Reply

Market Cap	381.10B
Revenue (ttm)	61.16B
Net Income (ttm)	4.23B
EPS (ttm)	N/A
PE Ratio	21.05
Forward PE	15.00
Profit Margin	6.91%
Debt to Equity Ratio	-11.02

Volume	1,752,271
Avg Vol	6,736,016
Day's Range	N/A - N/A
Shares Out	1.77B
Stochastic %K	74%
Beta	0.32
Analysts	Strong Sell
Price Target	$250.90